Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CELLECTAR22 DL-00001
Analyst Grade Summary
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
7
1
0
0
No Price
28.04.2026 20:00
Current Prices from CELLECTAR22 DL-00001
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
CLRB
USD
28.04.2026 20:00
2,56 USD
-0,05 USD
-1,92 %
IEX
CLRB
USD
21.04.2026 19:59
2,94 USD
-
Share Float & Liquidity
Free Float94,33 %
Shares Float3,01 M
Shares Outstanding3,19 M
Company Profile for CELLECTAR22 DL-00001 Share
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
